Iron stores and vascular function in voluntary blood donors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 8, 2005, Pages 1577-1583

  Zheng, Haoyi ^b   Cable, Richard ^b   Spencer, Bryan ^b   Votto, Nancy ^b   Katz, Stuart D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Ferritin; Nitric oxide; Oxidative stress; Vascular endothelium; Vasodilation

Indexed keywords

3 NITROTYROSINE; BIOCHEMICAL MARKER; FERRITIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD DONOR; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CORONARY RISK; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; IRON STORAGE; MALE; OUTCOMES RESEARCH; OXIDATIVE STRESS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VASODILATATION;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD DONORS; BRACHIAL ARTERY; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; RISK FACTORS; RISK REDUCTION BEHAVIOR; VASODILATION;

EID: 23244441664     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000174126.28201.61     Document Type: Article

References (48)

1. Zweier JL, Broderick R, Kuppusamy P, Thompson-Gorman S, Lutty GA. Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem. 1994;269:24156-24162.
2. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, Fay WP. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107:2601-2606.
3. Araujo JA, Romuno EL, Brito BE, Parthe V, Romano M, Bracho M, Montano RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbils. Arterioscler Thromb Vasc Biol. 1995;15:1172-1180.
4. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999;99:1222-1229.
5. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294.
6. Sullivan JL. Misconceptions in the debate on the iron hypothesis. J Nutr Biochem. 2001;12:33-37.
7. Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis? Transfusion. 2000;40:1023-1029.
8. Vane JR, Anggard EE, Hotting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
9. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004;109:2617-2625.
10. Mancini GB. Vascular structure versus function: is endothelial dysfunction of independent prognostic importance or not? J Am Coll Cardiol. 2004;43:624-628.
11. Pai JK, Pischon T, Ma J, Manson J, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
12. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804.
13. Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arteriosclcr Thromb Vasc Biol. 2002;22:E15-E18.
14. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273:402-407.
15. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-942.
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
17. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
18. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J. 2003;145:190-194.
19. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488.
20. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447-452.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
22. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Grouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
23. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990;186:1-85.
24. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833-840.
25. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol. 2000;20:1430-1442.
26. Finch CA, Cook JD, Labbe RF, Culala M. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood. 1977;50:441-447.
27. Milman N, Kirchhoff M. The influence of blood donation on iron stores assessed by serum ferritin and hemoglobin in a population survey of 1359 Danish women. Ann Hematol. 1991;63:27-32.
28. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. Heart. 1997;78:188-193.
29. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood conation on incident cardiac events. Transfusion. 2002;42:1135-1139.
30. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314:793-794.
31. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation. 2001;103:52-57.
32. Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, Briancon S, Malvy D, Roussel AM, Favier A, Hereberg S. Determining factors in the iron status of adult women in the SU.VI.MAX study. SUpplementation en Vitamines et Mineraux AntioXydants. Eur J Clin Nutr. 1998;52:383-388.
33. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidams hy myeloperoxidase in monocytes: pathways for monocyte-mediatcc protein nitration and lipid peroxidation In vivo. Circ Res. 1999;85:950-958.
34. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastitin in rats with heart failure alter myocardial infarction. Circulation. 2001;104:982-985.
35. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokee N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289:1675-1680.
36. Zacharski LR, Gerhard GS. Atherosclerosis: a manifestation of chronic iron toxicity? Vasc Med. 2003;8:153-155.
37. Miller VM, Vanhoutte PM. Enhanced release of endothelium-derived relaxing factor by chronic increases in blood flow. Am J Physiol. 1988;255:H446-H451.
38. Davies PF, Triputhi SC. Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res. 199372:239-245.
39. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, 3rd. Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505.
40. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004;291:711-717.
41. James PE, Lang D, Tufnell-Barret T, Milsom AB, Frenneaux MP. Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin. Circ Res. 2004;94:976-983.
42. Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A. Serial immunorcactive erythropoietin levels in autologuus blood donors. Transfusion. 1991;31:650-654.
43. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979.
44. Venna S, Buchanan MR, Anderson TJ. Endothelial function testing as a hiomarker of vascular disease. Circulation. 2003;108:2054-2059.
45. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.
46. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111:310-314.
47. Zacharski LR, Chow BK, Howes PS, Lavori PW, Shamayeva G. Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: The Iron (Fe) and Atherosclerosis Study (FeAST). Am Heart J. 2004;148:386-392.
48. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of hody iron stores in atherosclerotic peripheral vascular disease. Am Heart J. 2000;139:337-345.